- Blog
- News & Media
- Issues
- About The Biopharmaceutical Sector
- Access and Affordability
- Adherence
- Appropriate Use Of Medicines
- Counterfeit Drugs
- Disaster Response
- Drug Safety
- Environmental Issues
- Food And Drug Administration
- Importation
- Intellectual Property
- International
- Medical Advances
- Medicare
- Prescription Drug Abuse
- Prescription Drug User Fee Act
- Sales And Marketing
- Research
- About
The Biopharmaceutical Sector’s Impact on the Economy of Minnesota
This fact sheet presents an analysis of the impact of the biopharmaceutical sector on the economy of Minnesota (MN) in 2008, including data on employment, economic output, and research and development activity. The biopharmaceutical sector’s economic impact includes not only the direct impact of its companies, but also the ripple effects that the sector has throughout the rest of the economy. These ripple effects include both the indirect impact, the economic value of the goods or services used to support biopharmaceutical companies, and the induced impact, the value of the economic activity supported by the spending of the direct and indirect employees of the biopharmaceutical sector.
Additional Information on the Biopharmaceutical Sector’s Impact in Minnesota:
PhRMA commissioned Battelle to conduct this study to examine the extent to which state governments are targeting the industry for economic growth and development:
- Minnesota’s biopharmaceutical sector supports more than 49,000 workers and contributed $8.2 billion to the state’s economy in 2006, including direct, indirect and induced impacts
- The state is seeking to expand its biopharmaceutical sector
- Minnesota has created Bioscience Zones that offer incentives to attract firms to locate in proximity to the state’s research institutions
*Battelle state fact sheets use the latest data available at the time of publication. This may predate the data from the Archstone reports, which use 2008 data.
